Navigation Links
Regeneron Announces Appointment of Robert E. Landry as Senior Vice President, Finance and Chief Financial Officer
Date:9/10/2013

TARRYTOWN, N.Y., Sept. 10, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the appointment of Robert E. Landry as Senior Vice President, Finance.  Mr. Landry will also assume the position of Chief Financial Officer of Regeneron on October 1.  After 18 years as CFO, Murray A. Goldberg will transition to a new role as Senior Vice President, Administration in anticipation of his retirement at the end of 2014.

Mr. Landry brings over two decades of varied financial and operating experience in the global pharmaceutical industry, most recently as Senior Vice President and Treasurer of Pfizer, Inc.  He will report to Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  Mr. Landry will have responsibility for all financial functions, including Controller's, Treasury, Financial Planning, Tax, and Internal Audit.  In his new role, Mr. Goldberg will continue to have responsibility for Alliance Management and various administrative functions.

"Murray has been an integral member of the Regeneron senior management team for close to two decades and his contribution to our success as we grew from a development stage biotechnology company to one of the largest biotechnology companies in the world has been invaluable.  We are extremely fortunate that Murray will stay at Regeneron through 2014 to help us with the transition to a new CFO," said Dr. Schleifer.  "Bob Landry brings with him a breadth of domestic and international financial expertise at Pfizer and Wyeth.  We look forward to the valuable perspective he will bring, as we continue to expand our operations in the U.S. and globally."

"I am pleased to be able to join an organization that is known for its deep commitment to science and to bringing life changing medicines to patients," said Robert Landry.  "I am excited about this opportunity and look forward to working with the talented Regeneron management team."

Prior to serving as Senior Vice President and Treasurer of Pfizer, Mr. Landry held a variety of U.S. and international financial and general management positions at Wyeth and Pfizer including Senior Vice President – Finance, Pfizer's Diversified Businesses, Treasurer of Wyeth, Director of Sales and Marketing and Chief Financial Officer for Wyeth Pharmaceuticals' Australian and New Zealand affiliates, and various other assignments in both the pharmaceuticals business and the parent company.  Mr. Landry joined Wyeth after spending two years as an auditor with PricewaterhouseCoopers LLP.  He holds a B.B.A in Accounting from the University of Notre Dame.

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.  For additional information about the company, please visit www.regeneron.com.Contact Information:Manisha Narasimhan, Ph.D.Peter DworkinInvestor RelationsCorporate Communications914.847.512914.847.764manisha.narasimhan@regeneron.competer.dworkin@regeneron.com


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regenerons Eylea Now Captures One-Quarter Of Wet AMD Patient Share, Surpassing Share Of Roche/Genentechs Lucentis
2. Quarterly Financial Results and Development Program Updates - Research Report on Regeneron, DaVita, Celldex, Isis, and VIVUS
3. Regeneron Reports Second Quarter 2013 Financial and Operating Results
4. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
5. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
6. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
7. Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs
8. Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013
9. Regeneron Pharmaceuticals Announces Expansion in New Yorks Hudson Valley
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... New York , March 28, 2017 ... a largely consolidated vendor landscape, with the top three ... Agilent Technologies accounting for a significant 49% of the ... a recent report. The vendor landscape is intensely competitive ... share in the overall market. These factors have restricted ...
(Date:3/28/2017)... March 28, 2017 This ... these four stocks: The Medicines Co. (NASDAQ: MDCO), ... (NASDAQ: PCRX), and Supernus Pharmaceuticals Inc. (NASDAQ: ... Generic Drugs space which is governed by the ... drivers for the industry are wholesalers, retailers, pharmacies, ...
(Date:3/28/2017)... , March 28, 2017  Akcea Therapeutics, a subsidiary of ... the company,s board of directors: ... Mr. Gabrieli will serve as chairman of the board of ... chief commercial officer of Forest Laboratories. ... Partners. "We are excited to announce ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., ... (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products ... first of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and ...
(Date:3/28/2017)... ... 2017 , ... Calibration, qualification, and the appropriate level of ... GMP and USP compliance. In a new webinar from METTLER TOLEDO entitled “ ... requirements are explained. The challenge is to determine how to put the ...
(Date:3/28/2017)... Billerica, MA (PRWEB) , ... March 28, 2017 ... ... instrument for direct measurement of corrosive ions found in power plant water and ... plant components such as turbines and boilers, leading to extensive maintenance and unplanned ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... which will be offered by the American Association of Integrative Medicine and available ... for healthcare providers at the AutismOne 2017 Conference in Colorado Springs. , Ed ...
(Date:3/28/2017)... ... , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader in ... hair loss. Although hair transplant procedures can be seen as more of a man’s ... be two reasons a woman may see her hair thinning. , “We are used ...
Breaking Medicine News(10 mins):